Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: New Constructs, LLC
Provider: MacroRisk Analytics/EconomicInvestor

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Regeneron Pharmaceuticals Inc's Eylea Improves Vision In Another Eye Disorder-Reuters

Monday, 21 Oct 2013 08:19am EDT 

Reuters reported that Regeneron Pharmaceuticals Inc said its eye drug, Eylea, in a late-stage trial improved vision in patients suffering from a common form of vision loss caused by a blood clot in the veins of the retina. Eylea is already approved in the United States to treat wet age-related macular degeneration and for macular edema following central retinal vein occlusion. Both conditions cause vision loss. Regeneron said 53% of the patients who received Eylea gained at least 15 letters in vision, a measure of sharpness of vision, compared to 27% for those who received the standard therapy of laser treatment. The trial tested 183 patients with macular edema following branch retinal vein occlusion, a common disease in the elderly. The Company said 9.9% of patients in the Eylea group experienced serious adverse events, compared to 9.8% in the laser group. There was one serious adverse event in a patient receiving Eylea, Regeneron said. The patient suffered from a traumatic cataract, a cataract which is related to eye injury. Regeneron said common adverse events were bleeding from broken blood vessels in the eye and pain in the eye.